EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
EDAP TMS SA (Nasdaq: EDAP), a leader in robotic energy-based therapies, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Ryan Rhodes will engage in a fireside chat and conduct one-on-one investor meetings during the event.
The presentation is scheduled for Tuesday, September 9th, 2025, from 8:30-9:00 AM ET at the Lotte New York Palace Hotel. Investors can access both the live and archived webcast through the company's investor relations website.
EDAP TMS SA (Nasdaq: EDAP), leader nelle terapie robotiche a energia, ha annunciato la sua partecipazione al prossimo H.C. Wainwright 27th Annual Global Investment Conference. Il CEO Ryan Rhodes prenderà parte a un fireside chat e terrà incontri individuali con gli investitori durante l'evento.
La presentazione è fissata per martedì 9 settembre 2025, dalle 8:30 alle 9:00 AM ET presso il Lotte New York Palace Hotel. Gli investitori potranno seguire la webcasting in diretta e l'archivio video tramite il sito web per gli investitori della società.
EDAP TMS SA (Nasdaq: EDAP), líder en terapias robóticas con energía, ha anunciado su participación en la próxima H.C. Wainwright 27th Annual Global Investment Conference. El CEO Ryan Rhodes participará en un fireside chat y mantendrá reuniones individuales con inversores durante el evento.
La presentación está programada para el martes 9 de septiembre de 2025, de 8:30 a 9:00 AM ET en el Lotte New York Palace Hotel. Los inversores podrán acceder a la retransmisión en directo y al archivo webcast a través de la web de relaciones con inversores de la compañía.
EDAP TMS SA (Nasdaq: EDAP), 로봇 에너지 기반 치료 분야의 선도 기업은 다가오는 H.C. Wainwright 27th Annual Global Investment Conference에 참여한다고 발표했습니다. CEO Ryan Rhodes는 파이어사이드 채팅에 참여하고 행사 기간 중 투자자와의 일대일 미팅을 진행할 예정입니다.
프레젠테이션은 2025년 9월 9일 화요일, 오전 8:30~9:00 ET에 Lotte New York Palace Hotel에서 예정되어 있습니다. 투자자들은 회사 IR 웹사이트를 통해 라이브 웨비캐스트와 아카이브 영상을 이용할 수 있습니다.
EDAP TMS SA (Nasdaq: EDAP), leader des thérapies robotiques à énergie, a annoncé sa participation à la prochaine H.C. Wainwright 27th Annual Global Investment Conference. Le CEO Ryan Rhodes prendra part à un fireside chat et tiendra des rencontres individuelles avec des investisseurs lors de l'événement.
La présentation est programmée le mardi 9 septembre 2025, de 8h30 à 9h00 AM ET au Lotte New York Palace Hotel. Les investisseurs pourront accéder au webcast en direct et à l'archive via le site web relations investisseurs de la société.
EDAP TMS SA (Nasdaq: EDAP), ein führendes Unternehmen für robotergestützte energiebasierte Therapien, hat seine Teilnahme an der bevorstehenden H.C. Wainwright 27th Annual Global Investment Conference angekündigt. CEO Ryan Rhodes wird an einem Fireside-Chat teilnehmen und Einzelgespräche mit Investoren führen.
Die Präsentation ist für Dienstag, den 9. September 2025, von 8:30–9:00 AM ET im Lotte New York Palace Hotel angesetzt. Investoren können das Live- und das archivierte Webcast über die Investor-Relations-Website des Unternehmens abrufen.
- None.
- None.
AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.
Date: Tuesday, September 9th
Time: 8:30-9:00 AM ET
Location: Lotte New York Palace Hotel
Webcast: https://journey.ct.events/view/ede7e5df-b6f5-4ffb-a947-50a936dfb93b
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
When is EDAP's presentation at the H.C. Wainwright Conference 2025?
Who will represent EDAP at the H.C. Wainwright Conference 2025?
How can investors access EDAP's H.C. Wainwright Conference presentation?
What type of meetings will EDAP conduct at the H.C. Wainwright Conference?
